In the summer of 2026, medical AI projects at Hong Kong universities emerged as hotspots for capital investment. Multiple projects, including NaoSi Technology and Angxin Biotech, successfully secured funding. Previously, owing to the limited early-stage funding support available in Hong Kong, many entrepreneurs hailing from Hong Kong universities opted to establish their startup headquarters on the Chinese mainland. Consequently, a number of high-profile projects have already made their mark.

Beginning in 2026, the Special Administrative Region government has ramped up its investment in innovation and technology. Simultaneously, mainland Chinese capital has been flowing into Hong Kong in large amounts. Driven by a combination of factors such as valuation disparities, endorsement from the Hong Kong Investment Corporation, and the collaboration between Shenzhen and Hong Kong, Hong Kong universities have gradually transformed into a hub for technology procurement. This has given rise to a division of labor system where "R&D takes place in Hong Kong, and manufacturing occurs on the mainland." This model has significantly enhanced the efficiency of collaboration in the medical AI field, enabling PhD students from Hong Kong universities to access capital support without having to leave Hong Kong.

Moreover, entrepreneurs with a background from Hong Kong universities have also excelled in securing financing for sectors like embodied AI. Several universities in Hong Kong are actively working to improve the environment for medical startups, fostering a fertile ground for innovation and growth.